drugset / Trial / NCT06895356

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

NCT06895356

Phase 1 Completed 83 enrolled AbbVie
RandomizedCrossoverOpen-labelBasic science

Summary

This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.

Timeline

Start
2025-03-26
Primary completion
2025-06-16
Completion
2025-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule Oral

Indications

No indication recorded.